PDCD1 and head and neck squamous cell carcinoma: Based on the results of this clinical study KEYNOTE-048, in 2019 the Food and Drug Administration (FDA) approved pembrolizumab, that is the monoclonal antibody PD-1 (known with the brand name Keytruda), as a first-line therapeutic drug for patients with R/M-HNSCC.